Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybrid PET/MR for Treatment Response Prediction in MDD
NCT02711215Phase 4Unknown
- Sponsor
- Medical University of Vienna
- Start
- May 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Hamilton Depression Rating Scale at 12 weeks. Status: unknown.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02711215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711215.